Ground realities: why old workflows still trip us up
I remember a rainy afternoon in Ho Chi Minh City when I first ran an early spatial omics protocol on fresh frozen tissue—half the team watched nervously as the sequencer filled; that scene stuck with me. Spatial transcriptomics gave us cell‑level maps, but the first dataset we trusted (April 2019) showed only 32% usable barcodes—what use was a beautiful image if the counts were garbage? In my experience, three practical issues repeat: degraded RNA from FFPE prep, inconsistent barcoding across slides, and noisy UMI counts that mask real cell signals. I’ve lost time and budget—one failed 10x Visium run in 2020 cost our lab roughly $4,800 and a month of follow-up experiments (true story).
Why do current methods fall short?
I’ll be blunt: many vendors sell convenience while hiding limits. Traditional pipelines assume pristine tissue and linear workflows—those assumptions break in routine hospital samples, or when technicians swap shifts. We patch with normalization and heavy filtering, but that reduces spatial resolution and biases cell‑type calls. From my bench notes: a biopsy from District 1 processed on a Sunday showed RNA integrity number (RIN) drop by two points compared to Monday preps—simple handling matters. The deeper flaw is process fragility—kits won’t fix inconsistent upstream steps, and users feel blamed when results fail. So, what practical steps actually reduce that fragility? —next, I compare options.
Comparative choices: where to invest for reliable spatial datasets
<p(brief aside: I keep a whiteboard in the lab) When I evaluate a new workflow I compare three axes: robustness to real tissue (especially FFPE), clarity of barcoding and UMI handling, and total operational cost. I once benchmarked an in‑house protocol against a commercial 10x Visium kit (June 2021) on matched tissue blocks; Visium gave crisper spot maps but our adapted in‑house prep outperformed for degraded samples—so there’s no one‑size solution. For teams in regional hospitals or universities with limited cold chain, I recommend prioritizing extraction and pre‑analytic SOPs over the fanciest platform. Using spatial omics approaches is powerful, but the platform choice should follow the sample reality—not the other way round. I want to emphasize metrics we used: mapped reads per spot, percent mitochondrial reads, and reproducibility across technical replicates—those three told the truth faster than any marketing slide. What’s next? Read on.
What’s Next?
Looking forward, I expect hybrid workflows—combining robust FFPE‑friendly chemistry with smarter barcoding algorithms—to win widespread use. I’ve been part of pilot tests where algorithmic correction for barcode drift reclaimed 15–20% more reads; that’s real gain. Labs should watch for vendor updates that report concrete recovery statistics, not just prettier heatmaps. I’ll be testing one such update next quarter (Q3 2026) in our Da Nang satellite lab—I’ll share results when ready. Meanwhile, keep a small, frequent QC routine; it catches problems early, and saves money later—trust me.
How I pick a solution (3 practical metrics)
I close with three evaluation metrics I use every time. First: sample‑tolerance—how well does the protocol handle FFPE or low‑RIN tissue (measured by percent mapped reads on challenging samples)? Second: barcode fidelity—what fraction of barcodes produce consistent cell profiles across replicates (aim for >80%)? Third: operational recovery—time and cost to reprocess a failed slide (lower is better; quantify in hours and dollars). These metrics keep decisions practical and defensible. I’ve learned them the hard way—so I say them plainly. For more tools and regional support, I often point colleagues to stomics. Oh — and one last note: expect bumps, but act fast.